Cargando…

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

Pacritinib, potent inhibitor of Janus kinase 2 (JAK2), JAK2V617F, and fms-like receptor tyrosine kinase 3, is in Phase III development in myelofibrosis. Among type 1 inhibitors, pacritinib shows a lack of myelosuppression at doses that both inhibit JAK2/signal transducer and activator of transcripti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singer, Jack W, Al-Fayoumi, Suliman, Ma, Haiching, Komrokji, Rami S, Mesa, Ruben, Verstovsek, Srdan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993559/ https://www.ncbi.nlm.nih.gov/pubmed/27574472 http://dx.doi.org/10.2147/JEP.S110702

Ejemplares similares

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
por: Verstovsek, Srdan, et al.
Publicado: (2016)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis
por: Al-Fayoumi, Suliman, et al.
Publicado: (2018)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
por: Torres, Sandra, et al.
Publicado: (2023)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
por: Randhawa, Jasleen, et al.
Publicado: (2012)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
por: Anastassiadis, Theonie, et al.
Publicado: (2011)

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis COMFORT-I
por: Miller, Carole B., et al.
Publicado: (2017)

Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors
por: Zhong, Haizhen A., et al.
Publicado: (2023)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib
por: Yacoub, Abdulraheem, et al.
Publicado: (2023)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
por: Vannucchi, A., et al.
Publicado: (2022)

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
por: Mesa, Ruben A., et al.
Publicado: (2021)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
por: Chimalakonda, Anjaneya, et al.
Publicado: (2021)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
por: Singer, Jack W., et al.
Publicado: (2018)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Profile of pacritinib and its potential in the treatment of hematologic disorders
por: Hatzimichael, Eleftheria, et al.
Publicado: (2014)

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
por: Knight, Emily A., et al.
Publicado: (2015)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Role of janus kinase inhibitors in the treatment of alopecia areata
por: Triyangkulsri, Korn, et al.
Publicado: (2018)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4d02fp9fc3i6uk3c9debtuvbnd